Tags : Renal Data

AstraZeneca Reports Label Update with Positive Cardiovascular Outcomes and Renal

Tuba Khan August 5, 2019

Shots: The EC has approved label update which is based on Phase III DECLARE-TIMI 58 study results assessing Forxiga vs PBO on CV outcomes in 17,000 patients with T2D at […]readmore

Tags : Renal Data

AstraZeneca Reports Label Update with Positive Cardiovascular Outcomes and Renal

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Renal Data

﻿AstraZeneca Reports Label Update with Positive Cardiovascular Outcomes and Renal

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

AstraZeneca Reports Label Update with Positive Cardiovascular Outcomes and Renal